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Abstract  
 
The activities of total extracts and lupane triterpenes, isolated from the stem bark of Acacia mellifera, were 
evaluated against Plasmodium  berghei strain ANKA in a female Swiss mouse model. Five isolated compounds and 
the crude extracts were evaluated for antimalarial activity and Quinine hydrochloride was used as a positive control. 
Only betulin and the methanolic extract produced considerable antimalarial activity in mice infected with P. berghei 
parasites. This study demonstrated the presence of bioactive agents in Acacia mellifera.  
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Introduction 
 
Malaria is a disease of immense public importance. Available data suggest that there are 200-300 million cases, with 
more than two million deaths each year (Krogstad et al, 1990) out of which   one million is from the African 
continent alone [Daniel et al, 1988]. Chloroquine, a 4-aminoquinolone, has been the mainstay of malaria 
chemotherapy for almost 50 years now. This is because of its rapid onset of action, low toxicity and, almost low 
expense. It has remained the cheapest and most widely used antimalarial drug in parts of Africa (Daniel et al, 1988; 
Adubofour et al, 1992; WHO, 1984]. Chloroquine-resistant Plasmodium falciparum has been reported in parts of 
Africa (Le Bras et al, 1986; Sansonetti et al, 1985]. Resistance to chloroquine developed in Southeast Asia and 
South America at the end of the 1950s and in Africa by the late 1970s (Wharhurst, 2001]. Since the emergence of 
chloroquine resistant strains of P. falciparum, the rate of resistance has been increasing and limiting adequate 
treatment of malaria [Peters, 1998; Neequaye et al, 1986]. Consequently, there is an urgent global need to isolate 
from natural sources new classes of antimalarial compounds. A natural product artemisinin has previously shown 
excellent efficacy as non-alkaloidal, fast acting drug effective for chemotherapy against malaria (Ziffer et al, 1997]. 
Acacia mellifera has been reported to be used to treat malaria (Kokwaro, 1976] and used locally in Kenya traditional 
medicine. 
 As part of the search for new natural product for the treatment of various diseases (Mutai et al, 2004), we 
carried out a screening procedure to test A. mellifera total extract for the ability to treat malaria. On further 
purification of total extracts, pure metabolites were obtained and were also further investigated (Mutai et al, 2004].  
 
Materials and Methods 
Plant collection and Extraction 
 
Stem bark of A. mellifera was collected in January 2000, from at Machakos Kenya. The plant was 
authenticated at the East Africa Herbarium, National Museum of Kenya and a voucher specimen deposited at the 
same Institute in Nairobi, (Voucher number ChM-I). Air-dried, powdered stem bark of A.. mellifera (2.25 kg) was 
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extracted at room temperature, successively with dichloromethane (CH2Cl2) and methanol (MeOH) for 48 h each. 
The solvents were removed in vacuo to yield CH2Cl2 extract and MeOH extract. The extracts were each subjected 
separately to silica gel column chromatography eluted with a mixture of EtOAc and MeOH of increasing polarity. 
The purity of fractions was monitored using TLC. Identical fractions were pooled together. Further purification was 
done by rechromatography using gravity columns and then later subjected to HPLC. Six pure compounds namely: 
Acetylated epicatechin (4β-8) catechin from methanol extract and five lupan types (Figure 1): 3-(Z)-trans 
coumaroylbetulin, 3-(E)-cis coumaroylbetulin, 30-hydroxylup-20 (29)-en -3-one, Betulin and Lupeol from 
dichloromethane extract were isolated and their structures elucidated using spectroscopic methods. 
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Figure 1: Isolated compounds 
 
Parasites and Antimalarial Tests 
 
The Plasmodium berghei strain ANKA used in the study was obtained from Kenya Medical Research 
Institute (KEMRI). The parasite strain was propagated in mice and maintained by serial passage of infected 
erythrocytes. 
The antimalarial activity of the extracts or pure compounds was evaluated by the 4-day suppressive test 
described by Peters et al (1970, 1982). Adult female Swiss mice weighing 18-21 g were inoculated through i.p. route 
with 1 x 107 P.  berghei-infected erythrocytes. The mice were randomly divided into groups of five animals per cage 
and treated during 4 consecutive days with daily doses of the extracts, by oral route. Two control groups were used 
in each experiment; one treated with quinine at low non-curative dose (10mg/ kg/ day, orally) and the other group 
was kept untreated. Each day from day 0 to 4, parasites were determined in coded blood smears by randomly 
counting 2000-6000 erythrocytes in the case of low parasitaemia (≤10%) or up to 1000 erythrocytes in the case of 
higher parasitaemia. Overall mortality was monitored daily in all groups during a period of four weeks following 
inoculation. The inhibition of parasite growth in the drug-treated group was calculated. The extracts were considered 
partially active when parasitaemia was reduced by > 30%. 
 
Statistical analysis 
 
The statistical significance of differences in mean parasitemias between control and test groups were 
assessed using the Student t-test. P-values of 0.05 or less were considered statistically significant.  
 
Results and Discussion 
 
The results of the 4-day suppressive antimalarial screening of the total extracts/pure compounds (and 
Quinine Hydrochroride) at different doses in mice parasitized with P. berghei berghei are summarised in Tables 1 
and 2. The suppression of parasitemia expressed as percentage (S.P.; %) and standard deviations (n = 5) are given 
for each extract/drug. 
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Table 1: Mean chemosuppression of mice treated with total extracts 
Mean (S.D) value % 
Treatment Dose mg/kg/day 
Parasitemia Chemosuppression 
Control saline 31.97 (5.83) 0.0 (0.0) 
A 200 25.00 (0.57) 21.80 (1.77) 
A2 200 27.30 (2.31) 14.61 (7.21) 
M200 200 29.10 (2.69) 22.32 (1.79) 
M800 800 18.07 (2.80) 43.49 (8.77) 
Quinine Hydrochroride 10 3.03 (3.52) 90.51 (11.0) 
 
Key:  A     : Dichloromethane Extract; A2    : 25% dichloromethane in methanol Extract  
          M200: Methanol Extract 200mg/kg/day; M800: Methanol Extract 800mg/kg/day 
 
At 200 mg/kg the suppression of parasites was low: 21.80 % for dichloromethane extract, 14.6 % for 25 % 
dichloromethane in methanol extract, and 22.3 % for methanol extract. However, high dose for methanol extract 
(800 mg/kg), the percent of parasitemia suppression improved to 43.5 %. The three extracts had low antimalarial 
activities when compared to Quinine hydrochroride. The mean percentage parasitaemia in Quinine hydrochroride 
control group was 3.03 ± 3.52 %, while mean percentage parasitaemia in the untreated control was 31.97 ± 5.83%. 
The progression of parasitemia is shown in Figure 2. 
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Figure 2: Progression of parasitemia with time after treatment with total extracts 
 
The progression of parasitemia in animals treated with the pure compounds is shown in Figure 3. The antimalarial 
activity of total and pure compounds from A. mellifera in P. berghei-infected mice is shown in Tables 1 and 2 
respectiviely. The in vivo test showed that the dichloromethane (CH2Cl2) in 50% methanol (MeOH) extract at a dose 
of 200mg/kg was inactive because there was no significant reduction in the chemosuppression of parasitaemia on 
the fourth day. However, the dichloromethane (CH2Cl2) and MeOH extracts at the same dose, produced 
chemosuppression of parasitemia (> 21.8% and 22.3 % respectively) when administered orally. At a dose of 
800mg/kg, methanol extract produced the highest chemosuppression of parasitemia (> 43.5%) when administered 
orally. The profound chemosuppression of parasitemia of the methanol extract of this plant in our study underscores 
the need to study all parts of this plant  such  as  roots  and  the  leaves, 
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Table 2: Mean chemosuppression of mice treated with pure compounds. 
 
Mean (S.D) value % 
Treatment Dose mg/kg/day 
Parasitemia Chemosuppression 
Control Water 36.70 (6.22) 0.0 (0.0) 
ML 4 20 35.20 (7.41) 15.67 (3.27) 
ML 9 20 30.60 (2.77) 16.50 (7.55) 
ML 13 20 30.67 (2.77) 16.44 (7.56) 
ML 11 20 37.03 (2.55) 00.82 (8.86) 
ML 12 20 33.37 (10.49) 24.80 (12.33) 
ML 14 20 33.87 (5.91) 16.62 (6.55) 
Quinine 
Hydrochroride 10 04.85 (0.64) 86.79 (1.73) 
Key: ML 4: Acetylated epicatechin (4β-8) catechin; ML 9: 3-(Z)-trans coumaroylbetulin 
ML13: 3-(E)-cis coumaroylbetulin ; ML 11: 30-hydroxyl lupan-20 (29)-en -3-on 
ML 12 : Betulin; ML 14: Lupeol 
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Figure 3: Progression of parasitemia with time after treatment with pure compounds 
 
 which had been reported to be used also but not yet, documented.  
The MeOH extract showed slight mortality rate at the dose of 800mg/kg weight of mice as compared to 
non-treated mice.  This could be clear case of toxicity. The 3-(Z)-tran-coumaroylbetulin, lupeol and 3-(E)-cis-
coumaroylbetulin were found to have close values of chemosuppression of parasitemia which was not significant. 
The  parasitemia inhibition percent of betulin was the highest (24.8 %). This observation that betulin is not effective 
in vivo is consistent with earlier findings where it demonstrated in vitro inactivity at 500 mg/ml for both chloroquine 
resistant and sensitive P. falciparum [Steele et al, 1999]. However, the in vivo activity of betulin related triterpene; 
betulinic acid was ineffective at reducing parasitemia and also exhibited some toxicity [Steele et al, 1999]. On the 
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other hand, lupeol has been described to exhibit inhibitory activity on Plasmodium falciparum growth in vitro but 
lacks in vivo activity in mice infected with P. berghei (Alves et al., 1997). This result clearly indicated peculiarities 
in the metabolic disposition of the chemical constituents. Therefore, plants and pure compounds found to be active 
in vitro must be tested in vivo before a definite statement can be made on their antimalarial potential. 
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